Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | QDPR | P09417 | 2/20 | 0.52 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.51 |
| ▸ | GRM5 | P41594 | 3/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.49 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12479072 | 0.92 | QDPR (0.52) | NAMPTQDPRGRM1GRM5CDK7 | |
| SCHEMBL1781247 | 0.87 | LNPEP (0.48) | NAMPTQDPRGRM1GRM5CDK7 | |
| SCHEMBL17197366 | 0.87 | NAMPT (0.51) | NAMPTQDPRGRM1GRM5CDK7 | |
| SCHEMBL5869079 | 0.87 | NAMPT (0.55) | NAMPTGRM1GRM5CDK7CDK13 | |
| SCHEMBL12479794 | 0.87 | NAMPT (0.55) | NAMPTGRM1GRM5CDK7CDK13 | |
| SCHEMBL23411537 | 0.86 | QDPR (0.59) | NAMPTQDPRGRM1GRM5CDK7 | |
| SCHEMBL29891552 | 0.86 | QDPR (0.59) | NAMPTQDPRGRM1GRM5CDK7 | |
| SCHEMBL16992228 | 0.83 | QDPR (0.54) | NAMPTQDPRGRM1GRM5CDK7 | |
| SCHEMBL5869037 | 0.83 | NAMPT (0.52) | NAMPTGRM1GRM5CDK7CDK13 | |
| SCHEMBL17548155 | 0.83 | QDPR (0.56) | NAMPTQDPRGRM1GRM5CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| EP-2675794-B1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2019-02-13 | — | — | EP | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9174946-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-11-03 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| US-9120761-B2 | Selective FAK inhibitors | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2015-09-01 | — | — | US | disclosed |
| EP-2675794-A1 | SELECTIVE FAK INHIBITORS | Cancer Therapeutics Crc Pty Limited (AU) | 2013-12-25 | — | — | EP | disclosed |
| US-20130324546-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-12-05 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| WO-2012110774-A1 | SELECTIVE FAK INHIBITORS | CANCER THERAPEUTICS CRC PTY LIMITED (AU) | 2012-08-23 | — | — | WO | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324546-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | NAMPT 2847/4885QDPR 2799/4885GRM1 2033/4885 |
| US-20130022594-A1 | SELECTIVE FAK INHIBITORS | PTK2, CTTN, SRC | NAMPT 2728/4885QDPR 3114/4885GRM1 1678/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | NAMPT 186/4885QDPR 511/4885GRM1 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.